Suppr超能文献

R-维拉帕米:药代动力学及其对PR间期、血压和心率的影响

R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate.

作者信息

Ahmed J H, Godden J, Meredith P A, Elliott H L

机构信息

University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, Glasgow.

出版信息

Br J Clin Pharmacol. 1993 Aug;36(2):93-8. doi: 10.1111/j.1365-2125.1993.tb04202.x.

Abstract
  1. This study in healthy normotensive male volunteers investigated the pharmacokinetics and the effects on electrocardiographic PR interval, blood pressure and heart rate of single oral doses of the single isomer R-verapamil (250, 500 and 1000 mg) in comparison to placebo and 240 mg racemic verapamil. 2. After 500 and 1000 mg R-verapamil there were significant prolongations in PR interval, maximal at 1-2 h after dosing and coincident with peak plasma drug concentrations, but these were not significantly different from the maximum prolongation obtained with 240 mg racemic verapamil. 3. After 1000 mg R-verapamil there was a significant hypotensive effect, particularly on standing. 4. Single doses of 500 and 1000 mg R-verapamil produced peak plasma drug concentrations in the range 1000-3000 ng ml-1. If this concentration range is appropriate for adjuvant cancer chemotherapy it can be predicted that similar steady state concentrations will occur with a dosage regimen of 300 mg 3 times daily.
摘要
  1. 本研究在健康的血压正常男性志愿者中,调查了单剂量口服单一异构体R-维拉帕米(250、500和1000毫克)与安慰剂及240毫克消旋维拉帕米相比的药代动力学,以及对心电图PR间期、血压和心率的影响。2. 服用500和1000毫克R-维拉帕米后,PR间期显著延长,给药后1至2小时达到最大值,且与血浆药物浓度峰值同时出现,但这些与240毫克消旋维拉帕米所产生的最大延长值无显著差异。3. 服用1000毫克R-维拉帕米后有显著的降压作用,尤其是站立时。4. 500和1000毫克单剂量的R-维拉帕米产生的血浆药物浓度峰值在1000 - 3000纳克/毫升范围内。如果该浓度范围适用于辅助癌症化疗,可以预测,每日3次、每次300毫克的给药方案将产生相似的稳态浓度。

相似文献

1
R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate.
Br J Clin Pharmacol. 1993 Aug;36(2):93-8. doi: 10.1111/j.1365-2125.1993.tb04202.x.
2
Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study.
Eur J Clin Pharmacol. 2006 Aug;62(8):613-9. doi: 10.1007/s00228-006-0154-7. Epub 2006 Jul 4.
10
Pharmacokinetics of verapamil: experience with a sustained intravenous infusion regimen.
Am J Cardiol. 1982 Oct;50(4):716-21. doi: 10.1016/0002-9149(82)91224-3.

引用本文的文献

1
Novel Synergies and Isolate Specificities in the Drug Interaction Landscape of Mycobacterium abscessus.
Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0009023. doi: 10.1128/aac.00090-23. Epub 2023 Jun 6.
2
Evaluating the antidiabetic effects of R-verapamil in type 1 and type 2 diabetes mellitus mouse models.
PLoS One. 2021 Aug 6;16(8):e0255405. doi: 10.1371/journal.pone.0255405. eCollection 2021.
3
Abnormal vascular function in PR-interval prolongation.
Clin Cardiol. 2011 Oct;34(10):628-32. doi: 10.1002/clc.20958.
4
Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study.
Eur J Clin Pharmacol. 2006 Aug;62(8):613-9. doi: 10.1007/s00228-006-0154-7. Epub 2006 Jul 4.
5
Promising approaches in acute leukemia.
Invest New Drugs. 2000 Feb;18(1):57-82. doi: 10.1023/a:1006392116024.

本文引用的文献

2
Verapamil kinetics in normal subjects and patients with coronary artery spasm.
Clin Pharmacol Ther. 1981 Nov;30(5):644-52. doi: 10.1038/clpt.1981.216.
4
Predictability of verapamil steady-state plasma levels from single-dose data explained.
Clin Pharmacol Ther. 1984 Jul;36(1):1-4. doi: 10.1038/clpt.1984.129.
5
Preparation for retirement.
Br Dent J. 1969 Mar 4;126(5):235-6.
7
The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans.
Am Heart J. 1985 Feb;109(2):210-7. doi: 10.1016/0002-8703(85)90585-x.
10
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.
J Clin Oncol. 1987 Apr;5(4):641-7. doi: 10.1200/JCO.1987.5.4.641.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验